Shanghai Junshi Biosciences (HKG:1877) reported that loss attributable to owners for 2024 narrowed by 44% to 1.28 billion yuan, from the 2.28 billion yuan loss a year earlier, according to a Thursday filing with the Hong Kong bourse.
Loss per share was 1.30 yuan, from 2.32 yuan loss per share a year ago.
Revenue rose 30% to 1.95 billion yuan from 1.50 billion yuan the previous year.
The company's shares were up 6% at the Hong Kong bourse and 2% at the Shanghai bourse in recent trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。